Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Shire | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Shire

Revenues up 5% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Shire
2Q Revenues: $3.9 billion (+5%)
2Q Earnings: $616 million (+156%)
YTD Revenues: $7.7 billion (+5%)
YTD Earnings: $1.2 billion (+96%)
Comments: Immunology sales were $1.1 billion in the quarter, up 13% driven by Immunoglobulin therapies. Hematology sales were down 1% to $951.0 million. Neuroscience sales were up 9% to $693.7 million driven by Vyvanse and Adderall XR. Internal medicine revenues were up 61% to $232.9 million driven by Gattex and Natpara, up 77% and 88% respectively. Established product sales were down 36% to $218.5 million. In the quarter, Shire gained U.S. FDA approval for its plasma manufacturing facility near Covington, Georgia supporting its growing immunoglobulin portfolio.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters